There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Stoke Therapeutics (STOK – Research Report) and Trulieve Cannabis (TCNNF – Research Report) with bullish sentiments.
Stoke Therapeutics (STOK)
In a report released today, Jessica Fye from J.P. Morgan reiterated a Buy rating on Stoke Therapeutics, with a price target of $33.00. The company’s shares closed last Monday at $25.50.
According to TipRanks.com, Fye is a 5-star analyst with an average return of 16.0% and a 52.4% success rate. Fye covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Nektar Therapeutics, and Ascendis Pharma.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Stoke Therapeutics with a $38.00 average price target.
Trulieve Cannabis (TCNNF)
Trulieve Cannabis received a Buy rating and a $20.00 price target from Needham analyst Matt McGinley today. The company’s shares closed last Monday at $13.13.
According to TipRanks.com, McGinley is ranked #2176 out of 5717 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Trulieve Cannabis with a $20.41 average price target, representing a 55.9% upside. In a report issued on November 19, PI Financial also maintained a Buy rating on the stock with a C$20.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.